Harnessing bacteriocins for biotech and health
Syngulon is a synthetic biology startup developing bacteriocin-based technologies for biomanufacturing and health.
We harness bacteriocins, naturally occurring antimicrobial peptides, and their immunity systems to create innovative solutions in three areas: antibiotic-free selection for microbial production, precision control of microbial contamination, and targeted antimicrobial therapies.
Industry validation
In March 2026, we announced a non-exclusive licensing agreement with Elanco Animal Health, a global leader in animal health, granting worldwide access to our proprietary bacteriocin-based microbial selection technologies.
Our technologies are designed to complement existing industrial and pharmaceutical platforms and are available to partners through non-exclusive licensing.
Through its “Startup in the Labs” model, Syngulon combines its technology portfolio with close collaborations with academic laboratories and industrial partners worldwide.
Our ambition is simple: to turn the natural precision of bacteriocins into practical technologies for biotechnology and health.
Bacteriocins
Bacteriocins are ribosomally produced, genetically encoded antimicrobial peptides made by a wide variety of microorganisms. Their high specificity and diversity offer unique opportunities for biotechnology and health.
Synthetic biology makes it possible to engineer bacteriocins and their immunity systems, modify their spectrum of activity and design new functionalities. These properties form the scientific foundation of Syngulon’s technologies.
Syngulon is building PARAGEN, a collection of natural and synthetic bacteriocins that supports the development of our technologies and new applications.
+
Technologies
We harness the unique properties of bacteriocins to engineer innovative genetic technologies that address some of the most pressing challenges in biotechnology and health.
Our technology portfolio is structured around three core applications:
01
Sustainable alternatives to antibiotic resistance markers for recombinant protein production.
02
Advanced systems that actively protect industrial bioprocesses from microbial contamination.
03
Novel bacteriocin-based molecules offering targeted strategies against resistant pathogens.